tiprankstipranks
Mereo Biopharma Group Plc (MREO)
NASDAQ:MREO
Holding MREO?
Track your performance easily

Mereo Biopharma Group Plc (MREO) Income Statement

575 Followers

Mereo Biopharma Group Plc Income Statement

Last quarter (Q4 2022), Mereo Biopharma Group Plc's total revenue was £―, a decrease of ― from the same quarter last year. In Q4, Mereo Biopharma Group Plc's net income was £―. See Mereo Biopharma Group Plc’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
-£ 7.91M-£ 36.46M--
Cost of Revenue
-£ 11.94M£ 936.00K£ 17.91M-£ 23.61M
Gross Profit
-£ -4.02M£ -936.00K£ 18.56M-£ -23.61M
Operating Expense
-£ 28.95M£ 44.51M£ 39.49M£ 37.57M£ 15.91M
Operating Income
-£ -32.97M£ -45.44M£ -20.94M£ -37.57M£ -39.52M
Net Non Operating Interest Income Expense
-£ 68.00K£ -2.21M£ 4.02M£ 6.34M£ 4.45M
Other Income Expense
-£ -253.00K£ -8.62M£ 39.20M£ -122.54M£ 2.85M
Pretax Income
-£ -34.65M£ -41.07M£ 14.24M£ -166.45M£ -41.12M
Tax Provision
-£ -1.47M£ -1.90M£ 1.52M£ -2.82M£ -6.27M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-£ -33.18M£ -39.17M£ 12.72M£ -163.63M£ -34.84M
Basic EPS
--£ -0.06--£ -0.39
Diluted EPS
--£ -0.06--£ -0.39
Basic Average Shares
--£ 603.20M--£ 89.42M
Diluted Average Shares
--£ 603.20M--£ 89.42M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
-£ 40.88M£ 45.44M£ -57.40M£ -37.57M£ -39.52M
Net Income From Continuing And Discontinued Operation
-£ -33.18M£ -39.17M£ 12.72M£ -163.63M£ -34.84M
Normalized Income
-£ -36.11M£ -42.97M-£ -158.40M£ -48.88M
Interest Expense
------
EBIT
-£ -33.08M£ -38.16M£ 10.22M£ -160.07M£ -36.51M
EBITDA
-£ -32.23M£ -37.44M-£ -158.47M£ -34.94M
Currency in GBP

Mereo Biopharma Group Plc Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis